Comparative Pharmacology
Head-to-head clinical analysis: HALOETTE versus IMPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOETTE versus IMPLANON.
HALOETTE vs IMPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
One 13.9 mg subcutaneous etonogestrel implant inserted into the inner side of the non-dominant upper arm for contraception; effective for 3 years.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3–1.7 hours (mean 1.5 hours). The short half-life supports continuous intravenous infusion for sustained sedation in critical care.
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Renal excretion of metabolites accounts for approximately 85–90% of elimination; biliary/fecal excretion accounts for 10–15%.
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Category C
Category C
Contraceptive
Contraceptive